Multiple Sclerosis Treatment Research Takes a Nanotechnology Turn
Multiple sclerosis treatment research reached a significant milestone when scientists at the University of California, Irvine developed a nanotechnology based approach derived from bone marrow stem cells that successfully reversed MS symptoms in mice. The findings, published in the journal ACS Nano, open a new avenue for treating autoimmune and neurodegenerative diseases that have resisted conventional therapies.
The Problem with Conventional Stem Cell Therapies
Stem cell based treatments for conditions like multiple sclerosis have produced inconsistent results in clinical trials. A major reason, researchers say, is that scientists have not fully understood how the treatments work at a mechanistic level. When stem cells are injected intravenously, they are often intercepted and trapped in filter organs such as the liver and spleen before they can reach the central nervous system.
“Until now, stem cell therapies for autoimmune and neurodegenerative diseases have produced mixed results in clinical trials, partly because we don’t know how the treatments work,” said Weian Zhao, corresponding author and associate professor of pharmaceutical sciences and biomedical engineering at UC Irvine. “This study helps unravel that mystery and paves the way for testing with human patients.”
How the Nanotechnology Approach Works
To overcome the delivery problem, the research team took a different approach. Rather than injecting whole stem cells, they extracted nano sized particles called exosomes directly from bone marrow stem cells that had been activated with interferon gamma, an immune system protein. These exosomes, loaded with anti inflammatory and neuroprotective RNA and protein molecules, were then injected into mice with MS.
Because of their extremely small size, the exosomes were able to cross the blood spinal cord barrier, a biological checkpoint that blocks many larger therapeutic agents from reaching the nervous system. Once inside, they delivered their molecular cargo directly to the site of damage.
The results were striking. In addition to reversing lost motor skills and reducing nerve damage, the exosomes normalized the immune systems of the treated animals, something that conventional MS drugs are not capable of doing. Current disease modifying therapies can slow progression, but they do not address the underlying immune dysfunction that drives the disease. Multiple sclerosis treatment research has long sought a solution that goes beyond symptom management, and this nanotechnology approach represents a meaningful step in that direction.
What Comes Next in Multiple Sclerosis Treatment Research
The next phase of multiple sclerosis treatment research using this approach is already in planning. The novel treatment was initially scheduled for human trials in early 2020, beginning with patients with Type 1 diabetes, another autoimmune condition, before expanding to MS populations.
“If successful, it could pave the way for treating other autoimmune diseases, including multiple sclerosis,” said Milad Riazifar, co lead author and pharmacological sciences doctoral student, who at the time of publication was helping prepare for a City of Hope clinical trial of the method.
The study was supported by the National Institutes of Health, a National Institute of Neurological Disorders and Stroke training grant, and additional funding from private scholarship and research foundations. The breadth of institutional support behind this work reflects the scientific community’s recognition that nanotechnology based delivery systems represent a genuinely new frontier in autoimmune disease treatment.
The Role of Clinical Trials in Advancing New Therapies
Discoveries like this one underscore why robust clinical trial infrastructure matters. Translating a promising laboratory result into an approved human therapy requires multiple phases of rigorous testing across diverse patient populations. Phase I studies establish safety and dosing. Phase II evaluates immune response and preliminary efficacy. Phase III confirms results at scale across thousands of participants. Each phase generates the safety and efficacy data that regulators and the scientific community need before a treatment can reach patients.
FOMAT supports this process across a broad range of therapeutic areas, including neurology and autoimmune disease research. Our investigator network across the United States provides sponsors and CROs with the site access, patient diversity, and operational experience needed to move novel therapies from early phase studies into pivotal trials. To learn more about our active studies or our clinical trial capabilities, visit fomatmedical.com.
For More Information
To read the original source, click here